You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mismatch repair (MMR)

Showing 1 - 25 of 4,646
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Liver Metastases, MSS Trial (Sinti+Rego+Cele)

Not yet recruiting
  • Colorectal Cancer
  • +2 more
  • (no location specified)
Jul 3, 2023

s Microsatellite Instability Testing v Mismatch Repair in

Completed
  • Gastric Cancer
  • Mismatch repair
  • Truro, Cornwall, United Kingdom
    Royal Cornwall Hospital
Oct 6, 2020

Lynch Syndrome Based on Next-generation Sequencing in Colorectal

Completed
  • Lynch Syndrome
  • next-generation sequencing
  • Fuzhou, Fujian, China
  • +6 more
Jul 14, 2021

MSI-H Colorectal Cancer Trial (colorectal resection)

Completed
  • MSI-H Colorectal Cancer
  • colorectal resection
  • (no location specified)
May 22, 2023

Endometrial Cancer Trial in United States (Intensity modulated radiation therapy (IMRT), Dostarlimab)

Recruiting
  • Endometrial Cancer
  • Basking Ridge, New Jersey
  • +6 more
Jul 5, 2022

Metastatic Colorectal Cancer Trial in Baltimore (CY, GVAX, Pembrolizumab)

Completed
Has Results
  • Metastatic Colorectal Cancer
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Feb 8, 2021

Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

Recruiting
  • Recurrent Endometrial Adenocarcinoma
  • +8 more
  • Ipilimumab
  • Nivolumab
  • Iowa City, Iowa
  • +9 more
Jan 27, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)

Not yet recruiting
  • Endometrial Neoplasms
  • Endometrial Cancer
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
Mar 21, 2023

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair Trial in China (S1,

Not yet recruiting
  • Adenocarcinoma of the Stomach
  • +2 more
  • Hangzhou, Zhejiang, China
  • +4 more
May 23, 2023

Endometrial Adenocarcinoma, Endometrial Carcinoma, Lynch Syndrome Trial in United States (Genetic Counseling, Genetic Testing,

Active, not recruiting
  • Endometrial Adenocarcinoma
  • +3 more
  • Genetic Counseling
  • +3 more
  • Akron, Ohio
  • +8 more
Dec 2, 2022

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,

Recruiting
  • MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
  • Kashiwa, Chiba, Japan
    Novartis Investigative Site
May 2, 2023

Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)

Recruiting
  • Recurrent Endometrial Cancer
  • Solid Tumors
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 12, 2022

Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer Trial in Houston (Tecentriq 1200 MG in 20 ML Injection +

Not yet recruiting
  • Stage I Colon Cancer
  • +2 more
  • Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
  • +2 more
  • Houston, Texas
    Baylor College of Medicine
May 22, 2023

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Endometrial Cancer Trial (Anlotinib + Camrelizumab)

Not yet recruiting
  • Endometrial Cancer
  • Anlotinib + Camrelizumab
  • (no location specified)
Sep 26, 2022

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency Trial in New Brunswick (drug, other,

Recruiting
  • Epstein-Barr Virus Positive
  • +10 more
  • Atlanta, Georgia
  • +2 more
Dec 10, 2022

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)

Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting
  • Anal Squamous Cell Carcinoma
  • +7 more
  • Regorafenib in combination with Tislelizumab
  • (no location specified)
Oct 12, 2022

Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer Trial in Richmond (Lenvatinib, Pembrolizumab)

Recruiting
  • Endometrial Cancer
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University
Apr 5, 2022

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 22, 2022

Tumor Vaccine Benefit for Gliomas

Recruiting
  • Glioma
  • DC vaccine
  • Shanghai, China
    Huashan Hospital，Fudan University
Sep 12, 2023